Citi says the European Patent Office Board of Appeal invalidated a key Arbutus Biopharma (ABUS) delivery technology patent, which is a “clear wi…
Citi says the European Patent Office Board of Appeal invalidated a key Arbutus Biopharma (ABUS) delivery technology patent, which is a “clear win” for Moderna (MRNA). The invalidation neutralizes a “significant legal threat” for Moderna before the Un… [318 chars]
Source: Markets Insider | Published: 2026-01-19T17:30:39Z
Credit: Markets Insider
